Brief: Hookipa Achieves $10 Million Milestone Payment In Development Of Immunotherapy For Kras-Mutated Cancers
13/02/2023 12:22
Feb 13 (Reuters) - HOOKIPA Pharma Inc HOOK.O :
* HOOKIPA ACHIEVES $10 MILLION MILESTONE PAYMENT IN
DEVELOPMENT OF
IMMUNOTHERAPY FOR KRAS-MUTATED CANCERS
* HOOKIPA PHARMA INC - PLANS TO SUBMIT AN INVESTIGATIONAL
NEW DRUG
APPLICATION (IND) TO U.S. FOOD AND DRUG ADMINISTRATION IN FIRST
HALF OF 2024
Source text for Eikon: ID:nGNX63jP8h
Further company coverage: HOOK.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)